Antimicrobial resistance monitoring of 1 240 clinically isolated bacteria
10.3969/j.issn.1671-8348.2015.02.018
- VernacularTitle:1240株临床分离菌株耐药性监测
- Author:
Xi YANG
;
Lihang LIU
- Publication Type:Journal Article
- Keywords:
bacteria;
drug tolerance;
resistance monitoring;
methicillin-resistant staphylococcus;
extended spectrum beta-lacta-mases
- From:
Chongqing Medicine
2015;(2):197-200
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the bacterial distribution and resistance of clinical isolates ,so as to provide basis for the clinical medication .Methods The drug susceptibility testing was performed by Kirby‐Bauer method or automated system .The re‐sults were analyzed by WHONET 5 .6 referring to the breakpoints of CLSI 2013 .Results Of 1 240 clinical iso1ates ,the gram‐posi‐tive cocci and gram‐negative bacteria accounted for 32 .7% and 67 .3% respectively .The top five of isolated strains were Escherichia coli ,Klebsiella spp ,coagulase negative staphylococci ,Staphylococcus aureus ,Streptococcus pneumonia;the first five of isolated spec‐imens constitute followed by sputum ,urine ,blood ,secretions and stool .The average prevalence of methicillin‐resistant strains in S . aureus (MRSA) and coagulase‐negative Staphylococcus (MRCNS)was 17 .1% and 74 .7% ,respectively ;no vancomycin ,teicoplanin or linezolid‐resistant strains were found;no vancomycin‐resistant strains were found in Enterococcus spp;Enterobacteriaceae was still highly susceptible to imipenem and meropenem (> 85% );extended spectrum beta‐lactamases(ESBLs) producing strains ac‐counted for 56 .7% of Escherichia coli ,and accounted for 18 .6% of Klebsiella pneumonia;the drug resistance rates of Pseudomonas aeruginosa to imipenem was 11 .9% .The drug resistance rates of Acinetobacter spp to imipenem was 19 .0% .Conclusion The main infection site of patients in this hospital is respiratory tract and attention should be paid to docimastic sample .The top five clinical i‐solates and drug resistance are roughly the same with the results of Chongqing drug resistance monitoring net .
